Search
Avalo Therapeutics Inc
AVTXAdd to Watchlist
18.840USD
+1.550+8.96%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
335.87MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Avalo Therapeutics Inc is 8.92, ranking 34 out of 387 in the Biotechnology & Medical Research industry. The average price target is 35.00, with a high of 48.00 and a low of 24.00.
Analyst Rating
Based on
14
analysts
Strong Buy
Current Rating
46.182
Target Price
+167.10%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Avalo Therapeutics Inc
AVTX
14
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Avalo Therapeutics Inc's price target?
Analysts forecast that Avalo Therapeutics Inc's price target is USD 35.00, with the highest forecast at USD 48.00 and the lowest forecast at USD 24.00.
How have Avalo Therapeutics IncAVTX's recent earnings per share performed?
The market expectation was USD -0.98, while Avalo Therapeutics IncAVTX's earnings per share (EPS) for the previous quarter was USD -0.75. EPS for the next quarter is expected at USD -0.58.
What is the analyst rating for Avalo Therapeutics Inc?
Based on the ratings of Avalo Therapeutics Inc's stock from 14 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.